.Johnson & Johnson's deprioritization of its own transmittable condition pipeline has declared yet another victim in the form of its own dengue virus vaccine mosnodenvir.Mosnodenvir is made to block out interactions between 2 dengue infection proteins. The vaccine made it through J&J's decision in 2015 to merge its transmittable disease and vaccine operations, which observed the similarity a late-stage respiratory system syncytial infection program lost coming from the Major Pharma's pipeline and an E. coli vaccination sold to Sanofi.Mosnodenvir has actually possessed a bumpy ride in the medical clinic, along with J&J terminating one trial because of the impact of COVID-19 on enrollment and stopping recruitment in one more research in 2022. Yet the support to mosnodenvir seemed to repay in Oct 2023, when the injection was revealed to cause a dose-dependent antiviral effect on the detectability and also start of dengue infection serotype 3 in a phase 2 trial.
That records reduce doesn't show up to have been enough to save mosnodenvir for long, with the Big Pharma introducing today that it is actually terminating a follow-up stage 2 field study. The choice is associated with a "calculated reprioritization of the provider's pandemic health conditions R&D portfolio," incorporated J&J, which pressured that no safety issues had been actually pinpointed." Johnson & Johnson will certainly continue to assist the aggression against dengue through sharing study leads along with the clinical community later on," the pharma mentioned in the launch.J&J had actually been actually investing in dengue for over a many years, including releasing a Satellite Center for Global Health Discovery at the Duke-NUS Medical College in Singapore in 2022. The center has been actually paid attention to speeding up early-stage exploration study to "attend to the developing challenge of flaviviruses" like dengue as well as Zika.